250 related articles for article (PubMed ID: 18055238)
21. 3D-QSAR studies for the binding affinity toward (R, S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor.
Sharma RN; Thakar H; Vasu KK; Chaturvedi SC
Acta Pharm; 2008 Sep; 58(3):335-45. PubMed ID: 19103570
[TBL] [Abstract][Full Text] [Related]
22. Molecular modeling studies of N-substituted pyrrole derivatives--potential HIV-1 gp41 inhibitors.
Teixeira C; Barbault F; Rebehmed J; Liu K; Xie L; Lu H; Jiang S; Fan B; Maurel F
Bioorg Med Chem; 2008 Mar; 16(6):3039-48. PubMed ID: 18226912
[TBL] [Abstract][Full Text] [Related]
23. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
24. Towards predictive inhibitor design for the EGFR autophosphorylation activity.
San Juan AA
Eur J Med Chem; 2008 Apr; 43(4):781-91. PubMed ID: 17689836
[TBL] [Abstract][Full Text] [Related]
25. Molecular modeling studies on imidazo[4,5-b]pyridine derivatives as Aurora A kinase inhibitors using 3D-QSAR and docking approaches.
Lan P; Chen WN; Chen WM
Eur J Med Chem; 2011 Jan; 46(1):77-94. PubMed ID: 21093113
[TBL] [Abstract][Full Text] [Related]
26. 3D-QSAR and receptor modeling of tyrosine kinase inhibitors with flexible atom receptor model (FLARM).
Peng T; Pei J; Zhou J
J Chem Inf Comput Sci; 2003; 43(1):298-303. PubMed ID: 12546565
[TBL] [Abstract][Full Text] [Related]
27. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.
Lippa B; Kauffman GS; Arcari J; Kwan T; Chen J; Hungerford W; Bhattacharya S; Zhao X; Williams C; Xiao J; Pustilnik L; Su C; Moyer JD; Ma L; Campbell M; Steyn S
Bioorg Med Chem Lett; 2007 Jun; 17(11):3081-6. PubMed ID: 17398092
[TBL] [Abstract][Full Text] [Related]
28. 3D-QSAR and molecular docking studies of selective agonists for the thyroid hormone receptor beta.
Du J; Qin J; Liu H; Yao X
J Mol Graph Model; 2008 Sep; 27(2):95-104. PubMed ID: 18436460
[TBL] [Abstract][Full Text] [Related]
29. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
Holder S; Lilly M; Brown ML
Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
[TBL] [Abstract][Full Text] [Related]
30. Multitemplate alignment method for the development of a reliable 3D-QSAR model for the analysis of MMP3 inhibitors.
Tuccinardi T; Ortore G; Santos MA; Marques SM; Nuti E; Rossello A; Martinelli A
J Chem Inf Model; 2009 Jul; 49(7):1715-24. PubMed ID: 19522467
[TBL] [Abstract][Full Text] [Related]
31. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling.
Chen YD; Jiang YJ; Zhou JW; Yu QS; You QD
J Mol Graph Model; 2008 Apr; 26(7):1160-8. PubMed ID: 18061500
[TBL] [Abstract][Full Text] [Related]
32. Protein kinase inhibitors: insights into drug design from structure.
Noble ME; Endicott JA; Johnson LN
Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
[TBL] [Abstract][Full Text] [Related]
33. In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2.
Ahmed M; Sadek MM; Abouzid KA; Wang F
J Mol Graph Model; 2013 Jul; 44():220-31. PubMed ID: 23911931
[TBL] [Abstract][Full Text] [Related]
34. Design of Novel Chemotherapeutic Agents Targeting Checkpoint Kinase 1 Using 3D-QSAR Modeling and Molecular Docking Methods.
Balupuri A; Balasubramanian PK; Cho SJ
Curr Comput Aided Drug Des; 2016; 12(4):302-313. PubMed ID: 27585602
[TBL] [Abstract][Full Text] [Related]
35. Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening.
Zhang QY; Wan J; Xu X; Yang GF; Ren YL; Liu JJ; Wang H; Guo Y
J Comb Chem; 2007; 9(1):131-8. PubMed ID: 17206841
[TBL] [Abstract][Full Text] [Related]
36. 3D QSAR studies on GSK-3 inhibition by aloisines.
Zeng M; Jiang Y; Zhang B; Zheng K; Zhang N; Yu Q
Bioorg Med Chem Lett; 2005 Jan; 15(2):395-9. PubMed ID: 15603961
[TBL] [Abstract][Full Text] [Related]
37. Pharmacophore identification and validation study of CK2 inhibitors using CoMFA/CoMSIA.
Morshed MN; Muddassar M; Pasha FA; Cho SJ
Chem Biol Drug Des; 2009 Aug; 74(2):148-58. PubMed ID: 19563463
[TBL] [Abstract][Full Text] [Related]
38. CoMFA and docking studies of 2-phenylindole derivatives with anticancer activity.
Liao SY; Qian L; Miao TF; Lu HL; Zheng KC
Eur J Med Chem; 2009 Jul; 44(7):2822-7. PubMed ID: 19167135
[TBL] [Abstract][Full Text] [Related]
39. Potential choline kinase inhibitors: a molecular modeling study of bis-quinolinium compounds.
Srivani P; Sastry GN
J Mol Graph Model; 2009 Feb; 27(6):676-88. PubMed ID: 19147382
[TBL] [Abstract][Full Text] [Related]
40. New dual inhibitors of EGFR and HER2 protein tyrosine kinases.
Fink BE; Vite GD; Mastalerz H; Kadow JF; Kim SH; Leavitt KJ; Du K; Crews D; Mitt T; Wong TW; Hunt JT; Vyas DM; Tokarski JS
Bioorg Med Chem Lett; 2005 Nov; 15(21):4774-9. PubMed ID: 16111887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
